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Allopregnanolone is a metabolite of the sex hormone progesterone, with suggested
relevance for female mood disorders. While allopregnanolone and serotonin are known
to influence psychological well-being, the molecular and psychological specifics of their
relationship are to date poorly understood, especially in women of fertile age who
experience regular fluctuations of progesterone across the menstrual cycle. Availability
of serotonin in the synaptic cleft is regulated by the serotonin transporter (SERT), which
can be imaged in the living human brain by use of positron emission tomography
(PET) and the radiotracer [11C]DASB. To evaluate sex-specific allopregnanolone-SERT
interactions, the present study investigated the relationship between cerebral SERT
availability, serum allopregnanolone levels and psychological well-being in women
of fertile age. Brain imaging data, self-reported symptoms of mental distress and
emotion regulation, and biobank material from ninety healthy women were available
from the Center for Integrated Molecular Brain Imaging (CIMBI) database. Age, BMI,
and daylight minutes were included as covariates in the analyses and SERT genotype
(5-HTTLPR) was considered a potential confounder. Lower serum allopregnanolone
levels were associated with higher SERT binding in the prefrontal cortex. Moreover,
allopregnanolone levels were negatively associated with measures of alertness, although
this finding was not mediated by prefrontal cortex SERT binding. These findings suggest
a link between the typical psychological well-being experienced in the follicular phase
when allopregnanolone levels are low and higher SERT in the prefrontal cortex, a region
for higher cognitive functions and top-down regulation of emotions.
Keywords: allopregnanolone, brain, mood, PET, serotonin transporter, women, 5HTT
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INTRODUCTION
Progesterone is, together with estradiol, one of the ovarian
steroid hormones. Progesterone fluctuations are pronounced
during the menstrual cycle, but even more extreme variations
are noted across pregnancy and postpartum. Increasing evidence
suggest that progesterone influences emotion processing in
healthy, naturally cycling women (Toffoletto et al., 2014;
Comasco and Sundstrom-Poromaa, 2015). So far, earlier work
supports worsened emotion recognition, enhanced emotional
memory and increased amygdala reactivity at times of luteal
phase progesterone levels (van Wingen et al., 2008; Sundstrom
Poromaa and Gingnell, 2014). Furthermore, progesterone has
been implicated as a causal agent for premenstrual syndrome
and premenstrual dysphoric disorder (PMDD) (Sundstrom
et al., 1999; Segebladh et al., 2009). However, while it may
be assumed that some of these effects are mediated via
the progesterone receptor, some of the typical progesterone-
induced mood symptoms could equally well be mediated by
γ-aminobutyric acid (GABA)-active progesterone metabolites,
such as allopregnanolone (Backstrom et al., 2012). Of relevance,
allopregnanolone serum concentrations temporarily follow that
of progesterone during the menstrual cycle, but with an off-
set of one to two days (Ottander et al., 2005). Further, whereas
progesterone levels increase by 25-fold during the luteal phase,
allopregnanolone levels vary by approximately four-fold (Nyberg
et al., 2007).
Animal models point to sedative, anxiolytic, anti-convulsant,
and neuroprotective properties of allopregnanolone (Kask
et al., 2008; Melcangi et al., 2011; Brunton, 2015). In humans,
a distinct role of allopregnanolone for female mood disorders
has been difficult to delineate, and at present findings point
in two directions. First, in pregnant women low levels
of allopregnanolone have been associated with depressive
symptoms (Hellgren et al., 2014, 2017), and a proof-of-concept
study recently demonstrated that allopregnanolone infusion in
the postpartum period was able to rapidly alleviate postpartum
depressive symptoms (Kanes et al., 2017). On the other hand, in
terms of the menstrual cycle-induced mental health problems,
the allopregnanolone antagonist sepranolone was recently
demonstrated to hold promise as treatment of PMDD (Bixo
et al., 2017). These disparities in effect may be explained by
differences in underlying pathophysiology, but potentially
also by a suggested inverted U-shaped relationship between
allopregnanolone and psychological wellbeing (Backstrom
et al., 2014). The relationship between allopregnanolone and
serotonergic neurotransmission has received little attention in
humans, but animal studies have shown that acute administration
of fluoxetine increases allopregnanolone levels in the brain of
female rats (Fry et al., 2014; Devall et al., 2015) and diminishes
their sensitivity to stress (Devall et al., 2015). Clearly, further
studies are needed to elucidate the role of allopregnanolone in
female mood disorders, and its’ relationship with the serotonin
system.
Recently, menstrual cycle phase-dependent associations
between allopregnanolone and fMRI resting state functional
connectivity was demonstrated in healthy women
(Syan et al., 2017). In the mid-follicular phase, allopregnanolone
levels correlated negatively with resting state functional
connectivity between the seed region of the default mode
network, the posterior cingulate cortex, and the somatosensory
association cortex in the sensorimotor network. In the late
luteal phase, among other associations, allopregnanolone
levels correlated negatively with connectivity between another
region of the default mode network, the medial prefrontal
cortex (mPFC), and primary and association visual cortices,
but positively with connectivity between the mPFC and
the entorhinal cortex in the limbic system (Syan et al.,
2017). Moreover, a one-subject longitudinal study found
progesterone-dependent modulation of resting state connectivity
between the hippocampus and dorsolateral prefrontal cortex
(Arelin et al., 2015). Thus, the primary brain regions of
choice for this study were the midbrain, pallidostriatum
and prefrontal cortex, all important representatives of
serotonergic neurotransmission, and amygdala, insula, posterior
cingulate and hippocampus for their association to emotion
processing and allopregnanolone or progesterone-influenced
connectivity.
In terms of molecular imaging of markers of serotonergic
neurotransmission, no study to our knowledge has investigated
serotonin transporter (SERT) binding in relation to
allopregnanolone. Thus, the present study sought to investigate
cerebral SERT binding in relation to allopregnanolone serum
levels in women of childbearing age. Allopregnanolone
serum concentration was expected to negatively associate
with SERT availability, and also to influence measures of
mood.
MATERIALS AND METHODS
Subjects
Healthy women (age < 50 years) with regular menstrual cycle
(23–35 days), BMI < 50 kg/m2, and no use of hormonal
contraception or therapy, who had undergone PET scanning
on a high resolution research tomograph (HRRT) and had
a serum sample from the day of the PET scan stored in
the CIMBI Biobank (Knudsen et al., 2016) were included in
the study. With these criteria, serum samples of 92 women
who had undergone [11C]DASB scan were available for the
study. Two blood samples could not be analyzed for technical
reasons, leaving a study population of 90 healthy women for the
[11C]DASB analyses.
Besides exclusion criteria for neuroimaging, we excluded
subjects with clinically relevant medical history, such as
neurological or psychiatric disorders, and history of severe head
trauma, drug or alcohol abuse, or clinically relevant findings
on routine blood chemistry were excluded. All participants had
normal findings on brain magnetic resonance imaging (MRI) and
displayed no psychopathology according to the revised symptom
checklist (SCL-90-R) (Derogatis and Savitz, 1999) and the major
depression inventory (MDI). The participants have previously
been included as healthy volunteers in studies on GnRH
agonist treatment (Frokjaer et al., 2015; Macoveanu et al., 2016;
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Fisher et al., 2017a), serotonin transporter binding (Fisher et al.,
2017b), gastric bypass surgery (Haahr et al., 2015), and
functional connectivity (Beliveau et al., 2015). All projects
were approved by the Copenhagen Region Ethics Committee
(KF-01-2006-20, KF-01-124/04, H-1-2010-085, and H-2-2010-
108), and the women provided written informed consent for
participation.
Allopregnanolone Analyses
Blood samples were collected on the day of the PET scan.
The blood samples were centrifuged immediately after the
phlebotomy and plasma was stored at −20◦C. Allopregnanolone
plasma concentrations were determined by Umeå Neurosteroid
Research Center, in one batch, as previously described (Timby
et al., 2006). For measurement of allopregnanolone, we used
radioimmunoassay (RIA) after a first step involving extraction
with diethyl ether and purification by celite chromatography,
the latter to reduce cross-reactivity. The antibody used in the
RIA had been raised against 3α-hydroxy-20-oxo-5α-pregnan-
11-yl carboxymethyl ether coupled with bovine serum albumin
(AgriSera AB, Umeå, Sweden). A RackBeta (Wallace, Finland)
scintillation counter was used to count the samples. The
allopregnanolone detection limit was 25 pg/ml, with intraassay
coefficient of variation for of 6.5% and an interassay coefficient of
variation of 8.5%.
SERT Imaging
SERT binding was imaged with [11C]DASB-PET during a
90- min dynamic acquisition directly following the bolus
injection of the tracer. A Siemens ECAT HRRT scanner (Siemens,
Munich, Germany), operating in three-dimensional acquisition
mode, with an in-plane resolution of 2 mm, was used to obtain
the PET scans. The outcome of the [11C]DASB binding was the
ratio between specific binding and non-displaceable binding of
the tracer. We used a modified reference tissue model, using
cerebellum as a reference region (the vermis part excluded),
designed to quantify [11C]DASB (multilinear reference tissue
model/multilinear reference tissue model 2) (Ichise et al., 2003),
and implemented in PMOD (version 2.9; PMOD Technologies,
Zurich, Switzerland). Movement correction was performed by
AIR (Woods et al., 1992). The co-registration of the [11C]DASB
mean image to the high-resolution T1-weighted MR image was
done using SPM8 (Ashburner and Friston, 1997). The exact
details on the [11C] DASB imaging has been presented previously
(Frokjaer et al., 2009).
Volumes of Interest
Volumes of interest for this study were outlined on the
participant’s MRIs, as described previously (Svarer et al., 2005).
In order to constrain the number of statistical comparisons
we pooled a number of regions. This approach was based on
the observation of high correlation of SERT binding between
cortical and high-binding subcortical regions (Erritzoe et al.,
2010). Thus, an average SERT binding potential was computed
for each participant for the prefrontal cortex (computed by
pooling orbito-, superior-, and medial- and inferior-frontal
cortex), the pallidostriatum (a combined subcortical region), and
the midbrain (including the raphe nuclei). These three VOIs were
the primary outcomes of the study. In addition, four regions
served as secondary VOIs; amygdala, insula, hippocampus, and
posterior cingulate cortex. We chose these VOIs as SERT binding
in these regions is relevant in relation to previously described
allopregnanolone actions (Arelin et al., 2015; Syan et al., 2017).
Time-activity curves from the VOIs and cerebellum (nonspecific
binding) were only obtained from gray matter voxels, except
in the midbrain, where separation of gray and white matter is
difficult.
Mood, and Alertness
Emotional functioning and mood symptoms were assessed using
the following questionnaires: Profile of Mood States (POMS);
Cohen’s Perceived Stress Scale (PSS); Symptom Checklist-revised
(SCL); and Global Severity Index of SLC score (SCL-GSI).
A Simple Reaction Time task was performed to measure general
alertness and motor speed, as described in (Stenbaek et al.,
2016).
5-HTTLPR
The serotonin transporter-linked polymorphic region
(5-HTTLPR) (Heils et al., 1996; Lesch et al., 1996) was genotyped
in 87 of the participating women, as described in (Kalbitzer
et al., 2010). Genotype frequencies were in Hardy-Weinberg
equilibrium; SS = 22.2%, SL = 41.1%, and LL = 33.3%).
Statistics
The association between allopregnanolone serum concentrations
and SERT binding was evaluated by multiple linear regression
models. Previous findings have indicated that cerebral SERT
binding is influenced by season, age (declining with increasing
age), and body mass index (BMI) (Kalbitzer et al., 2010;
Tyrer et al., 2016). For these reasons, the weighted least
square regression models of SERT binding included age, BMI,
and daylight minutes as covariates, all entered as continuous
variables. Because allopregnanolone levels were not normally
distributed, we also weighted the regression models against
the rank order of allopregnanolone. Further all models were
carefully checked to ensure that unstandardized residuals were
normally distributed. Finally, we validated the weighted least
square regression models by use of robust linear regression using
an MM estimator.
Path analysis, with bootstrapping to yield confidence intervals
for the indirect effect, was performed to evaluate if the effect
of allopregnanolone on simple reaction latency was mediated
by prefrontal cortex SERT binding. Statistical analyses were
performed by SPSS 24.0, SPSS Amos 24.0, and R 3.4.3 using the
RobustBase 0.92 package.
RESULTS
As described in Table 1, women were on average young adults,
slightly over-weight and healthy from a psychiatric perspective.
According to normative allopregnanolone levels (Nyberg et al.,
2007), the majority of women was assessed in the follicular phase,
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TABLE 1 | Demographic data, allopregnanolone levels, and [11C]DASB binding in
the brain.
n = 90
Mean ± SD Range
Age, years 27.4 ± 8.2 18–49
BMI, kg/m2 25.4 ± 6.3 17.0–43.9
Allopregnanolone, nmol/l 0.61 ± 0.50 0.13–3.70
Estradiol, pmol/la 203 ± 130 60–810
Progesterone, nmol/la 0.2 ± 0.13 0.06–0.8
Daylight, minutes 739 ± 201 426–1052
SCL global severity index 0.3 ± 0.2 0.01–1.16
Total Mood Disturbance score 5.7 ± 20.5 −21–86
[11C]DASB BPND
Prefrontal cortex 0.38 ± 0.09 0.12–0.61
Midbrain 2.06 ± 0.29 1.22–2.71
Pallidostriatum 1.98 ± 0.35 1.12–3.02
Total amygdala 1.78 ± 0.35 0.82–3.04
Total insula 0.89 ± 0.14 0.42–1.32
Total hippocampus 0.71 ± 0.13 0.33–1.09
Total posterior cingulate 0.49 ± 0.10 0.16–0.69
Injected dose, MBq 571 ± 56 360–642
Injected mass per kilo, µg/kg 0.03 ± 0.04 0.00–0.24
Specific activity, GBq/mmol 177 ± 136 10.0–675
aEstradiol and progesterone serum concentrations only available in 72 women.
SCL-GSI, Global Severity Index of the Symptom Checklist-revised score.
TABLE 2 | Multiple linear regression analyses on allopregnanolone influence on
[11C]DASB binding.
Slope Adjusted
estimate SD β padj R2
Prefrontal cortex −0.038 0.017 −0.248 0.024 0.06
Midbrain −0.070 0.048 −0.149 0.147 0.16
Pallidostriatum −0.172 0.006 −0.302 0.005 0.10
Total amygdala −0.116 0.062 −0.146 0.067 0.06
Total insula −0.072 0.025 −0.300 0.005 0.11
Total hippocampus −0.062 0.022 −0.293 0.006 0.13
Total posterior cingulate −0.044 0.016 −0.264 0.008 0.23
Models adjusted for age, BMI, daylight minutes on the scanning day, and weighted
against rank order of allopregnanolone levels.
82/90 (91.1%). The highest SERT binding levels on average were
found in the midbrain and pallidostriatum, whereas the lowest
levels were noted in the prefrontal cortex and posterior cingulate
(Table 1).
Serum allopregnanolone levels were negatively associated with
SERT binding in the prefrontal cortex, pallidostriatum, insula,
posterior cingulate, and hippocampus (Table 2 and Figure 1).
Overall, the models, which also included age, BMI and daylight
minutes, explained 6–23% of the variance in SERT binding levels
across regions of interest, with the highest explanatory value in
the midbrain, and the lowest in the prefrontal cortex (prefrontal
cortex: (slope = −0.038, SD = 0.017, β = −0.248, p = 0.024)
FIGURE 1 | Linear association between prefrontal cortex SERT binding and
serum allopregnanolone level in women of fertile age, slope = –0.038,
SD = 0.017, β = –0.248, p = 0.024.
TABLE 3 | Correlations between allopregnanolone and mood proxies.
n Spearman Rho p
POMS Total Mood Disturbance (TMD) score 75 0.176 0.132
SCL-GSI 90 0.136 0.202
Cohen PSS 89 0.015 0.891
SRT total mean reaction latency 64 −0.267 0.033
SRT percent correct trials 64 −0.309 0.013
POMS, Profile of Mood States; PSS, Perceived Stress Scale; SCL, Symptom
Checklist-revised; SCL-GSI, Global Severity Index of SLC score; SRT, Simple
Reaction Test; TMD, Total Mood Disturbance. SRT, Simple Reaction Task.
(Table 2). However, the only allopregnanolone association
that survived robust regression was the one with SERT
binding in the prefrontal cortex (slope = −0.011, SD = 0.003,
β = −0.196, p < 0.001), whereas the robust regressions between
allopregnanolone and SERT binding in the pallidostriatum and
hippocampus were in borderline significance (pallidostriatum;
slope =−0.162, SD = 0.083, β =−0.236, p = 0.054, hippocampus;
slope = −0.049, SD = 0.027, β = −0.187, p = 0.071). Further, the
negative association between allopregnanolone and prefrontal
cortex SERT binding remained when also adjusted for estradiol
levels (slope = −0.092, SD = 0.029, β = −0.359, p = 0.002,
n = 70). Considering 5-HTTLPR genotype, as a proxy of SERT
functionality, did not influence any of the above mentioned
findings (tested both as first order effects and interactions).
Allopregnanolone levels were negatively correlated with mean
reaction latency and percent correct trials in the Simple Reaction
Test, Table 3 and Figure 2. Women who reacted slower displayed
higher allopregnanolone levels, and similarly, made more errors
(Table 3). The path analysis revealed that allopregnanolone
exerted a significant direct effect on frontal cortex SERT
binding (standardized estimate −0.321, p = 0.034) and a
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FIGURE 2 | Linear association between mean reaction latency in the simple
reaction test and allopregnanolone levels in women of fertile age, Spearman’s
rho = –0.267, p = 0.033.
borderline significant effect on reaction latency (standardized
estimate −0.179, p = 0.061). However, the indirect effect of
allopregnanolone on reaction latency, mediated by prefrontal
cortex SERT binding in the path model, was insignificant
(standardized estimate −0.066, p = 0.061). Allopregnanolone
serum concentrations did not influence any of the emotion- or
stress-related measures (Table 3).
DISCUSSION
Mapping of the allopregnanolone-serotonin transporter
relationship in women of fertile age demonstrated a negative
correlation between peripheral levels of this neuroactive steroid
and prefrontal cortex availability of the protein responsible
for serotonin re-uptake from the synaptic cleft. The major
limitations of this study was that measurements were mostly
performed in the follicular phase, and that the study only
included healthy women.
Allopregnanolone, produced both by the ovaries and in
the brain, acts not only as a transcription regulator but also
as a GABA agonist by binding to its site on the GABA
receptor A (GABAA). Allopregnanolone binding to the GABAA
receptor leads to enhanced chloride ion flow and decreased
GABA unbinding, which is reflected by increased frequency
of inhibitory postsynaptic current and desensitization of the
receptor (Wang, 2011). With GABA being the major inhibitory
neurotransmitter in the brain, present in one third of all
synapses, the effects of allopregnanolone are expected to be
widely spread, albeit with some differences, depending on
the localization and subunits of the GABAA receptor (Wang,
2011). As the women in this study were assessed at a time-
point when progesterone and allopregnanolone levels are low,
the present findings may reflect interactions between SERT
and GABA-mediated tonic conductance at the extra-synaptic
level, via α4β2δ GABA receptors (Wang, 2011). Presence of
GABAA receptors outside the synaptic cleft has been shown
in the hippocampal formation and cortex (Wang, 2011), brain
regions expressing SERT. Additionally, phasic modulation of
neuronal excitability by GABA can be also influenced by synaptic
GABAA receptors found ubiquitously in the brain (Wang, 2011).
Clearly, longitudinal investigations will be needed to understand
the relationship between serotonergic neurotransmission and
fluctuations of allopregnanolone and mood across the menstrual
cycle.
The present findings highlight a relationship between
allopregnanolone and SERT, particularly in the prefrontal cortex.
In this key region for higher cognitive functions and top-
down regulation of emotions, GABA as well as serotonergic
projections are widespread (Mengod et al., 2015). Some
evidence on GABA-serotonin reciprocal modulation may be
derived from animal studies (Svensson et al., 2000; Yan,
2002), but human data is scarce. In terms of molecular
imaging of markers of serotonergic neurotransmission in
relation to progesterone, 5-HT1A receptor binding was negatively
correlated with progesterone at the whole brain level in
postmenopausal women (Stein et al., 2014), whereas combined
estrogen-progesterone treatment in postmenopausal women
was associated with widespread increased cortical 5-HT2A
receptor binding (Moses et al., 2000; Moses-Kolko et al., 2003).
However, binding of these two receptors did not correlate with
progesterone in another study of pre- and post-menopausal
women (Moses-Kolko et al., 2011). To our knowledge, this
is the first study investigating SERT binding in relation to
the progesterone metabolite allopregnanolone in women of
fertile age.
Higher SERT in the presence of low allopregnanolone levels,
and independently of estradiol levels, may explain psychological
well-being during the follicular phase of the menstrual cycle. In
fact, no association of allopregnanolone with mood and stress
was found in this group of healthy women, likely because of the
healthy state and the limited variation in these measures during
the follicular phase. Previously, lower SERT binding has been
associated with depression (Parsey et al., 2006; Newberg et al.,
2012). Dysregulation of both allopregnanolone and serotonin
have been implicated in anxiety, irritability aggressiveness, as well
as cognitive impairment (Schule et al., 2014); however, knowledge
of their interaction at the molecular level is scarce. While
enhancing effects of SSRIs on peripheral allopregnanolone levels
have been demonstrated (Uzunov et al., 1996; Griffin and Mellon,
1999; Pinna et al., 2009), effects in the other direction remain to
be studied. Additionally, neurotrophic-like functions have been
demonstrated for both allopregnanolone and serotonin, though
more limited to developmental stages for serotonin (Whitaker-
Azmitia, 2001); and brain-derived neurotrophic factor (BDNF)
may be one link. The less functional variant of a polymorphism
in the brain derived-neurotrophic factor gene (BDNF), but
not the short allele of 5-HTTLPR, has for example been
associated with decreased fronto-cingulate activity in response
to emotional stimuli in PMDD patients in the luteal phase
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(Comasco et al., 2014). In line, no 5-HTTLPR genotype effect was
observed in the present study.
We found a negative association between allopregnanolone
and general alertness, as measured by the Simple Reaction
Test. This finding was expected, given the agonistic effects of
allopregnanolone on the GABAA receptor (Wang, 2011). In
line with a direct effect on the GABAA receptor, we found no
evidence that slower reaction times was mediated by lower SERT
binding.
CONCLUSION
To conclude, considering strengths and limitations of the study,
the present findings add knowledge to our understanding
of allopregnanolone-SERT neurochemistry in brain regions
regulating cognition and emotion processing of potential
relevance for sex-specific psychiatric disorders. Further studies
with samples from the luteal phase, and also including
women with diagnosed PMDD, are needed before a full
interpretation of the allopregnanolone-SERT relationship can be
made.
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